United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $517.51, for a total value of $4,916,345.00. Following the completion of the sale, the chief executive officer owned 324,443 shares in the company, valued at approximately $167,902,496.93. This represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
United Therapeutics Stock Performance
Shares of UTHR stock opened at $510.38 on Tuesday. United Therapeutics Corporation has a 1 year low of $303.08 and a 1 year high of $609.35. The firm has a market capitalization of $21.89 billion, a PE ratio of 18.26, a price-to-earnings-growth ratio of 1.75 and a beta of 0.59. The stock has a fifty day moving average of $529.90 and a two-hundred day moving average of $539.42.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period last year, the company earned $6.41 earnings per share. The company's quarterly revenue was down 1.9% compared to the same quarter last year. Equities research analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research firms have commented on UTHR. JPMorgan Chase & Co. raised their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a research note on Thursday, July 23rd. Wells Fargo & Company raised shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a report on Thursday, August 6th. TD Cowen reiterated a "buy" rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, Royal Bank Of Canada lowered their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a research note on Thursday, August 6th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, United Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $646.00.
Read Our Latest Report on United Therapeutics
Institutional Trading of United Therapeutics
Large investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System grew its position in United Therapeutics by 55,526.2% in the second quarter. California State Teachers Retirement System now owns 33,288,952 shares of the biotechnology company's stock worth $18,036,953,000 after buying an additional 33,229,108 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of United Therapeutics during the 2nd quarter valued at $2,868,735,000. Wellington Management Group LLP lifted its position in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company's stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares during the last quarter. Jupiter Topco LLC bought a new stake in shares of United Therapeutics during the 2nd quarter worth $450,140,000. Finally, Norges Bank bought a new stake in shares of United Therapeutics during the 4th quarter worth $293,418,000. 94.08% of the stock is currently owned by institutional investors.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
